FIELD: biotechnologies.
SUBSTANCE: invention proposes a humanised monoclonal antibody or its fragment including variable regions of light and heavy chains obtained from a mouse monoclonal antibody mBAT-1 in a combination with at least one chemotherapeutic agent based on platinum, antimetabolites or paclitaxel for treatment of a tumour disease. The invention describes use of a humanised monoclonal antibody or its fragment including variable regions of easy and heavy chains obtained from a mouse monoclonal antibody mBAT-1, in a combination with at least one chemotherapeutic agent based on platinum, antimetabolites or paclitaxel to improve survivability of an individual with tumour, who is treated at least with one chemotherapeutic agent.
EFFECT: synergetic effect expressed in increase of survivability of lymphocytes or decrease of tumour volume in comparison to use of h-BAT, which can be used in medicine for tumour treatment.
11 cl, 20 dwg, 2 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VERSIONS OF HUMANIZED IMMUNOMODULATORY MONOCLONAL ANTIBODIES | 2012 |
|
RU2604814C2 |
| COMBINATION THERAPY USING ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2789478C2 |
| COMBINED THERAPY USING THE ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2665321C2 |
| COMBINED THERAPY WITH USE OF CLAUDIN 18,2 ANTIBODIES FOR CANCER TREATMENT | 2013 |
|
RU2662066C2 |
| PD-1/PD-L1 INHIBITORS FOR TREATING CANCER | 2016 |
|
RU2742312C1 |
| USE OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE IN THE TREATMENT OF UROTHELIAL CARCINOMA | 2019 |
|
RU2750817C1 |
| PD-1/PD-L1 INHIBITORS FOR TREATING CANCER | 2016 |
|
RU2714233C2 |
| METHODS OF TREATING CANCER USING PD-1 AXIS BINDING AND VEGF ANTAGONISTS | 2013 |
|
RU2689760C2 |
| COMPOSITIONS AND METHODS OF TREATING AND DIAGNOSING CANCER-RESISTANT CANCER | 2015 |
|
RU2710735C2 |
| MEDICATION FOR TREATMENT OF LIVER CANCER | 2009 |
|
RU2523897C2 |
